Deakin University
Browse

File(s) under permanent embargo

An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder

Version 2 2024-06-02, 13:18
Version 1 2015-03-18, 12:04
journal contribution
posted on 2024-06-02, 13:18 authored by Michael BerkMichael Berk, AD du Plessis, M Birkett, D Richardt, Lilly Duloxetine Depression Study Group
Duloxetine hydrochloride, a mixed reuptake inhibitor of serotonin and noradrenaline, was studied in a 6 week open-label uncontrolled multicentre design at a dose of 20 mg daily both in in- and outpatients meeting DSM-III-R criteria for unipolar major depressive disorder. Seventy-nine patients took part in the study. The mean score on the 17-item Hamilton Depression Rating Scale at baseline was 24.9 (SD 4.4), decreasing to 8.5 (SD 7.8) after 6 weeks using a last observation carried forward analysis. Clinical response, defined as a 50% reduction in 17-item Hamilton Depression Rating Scale scores, occurred in 78.2% of patients, whereas remission, defined as a 17-item Hamilton Depression Rating Scale score of < or = 6, occurred in 60.3% of patients. Duloxetine hydrochloride was safe and well tolerated in this patient population.

History

Journal

International Clinical Psychopharmacology

Volume

12

Pagination

137-140

Location

Philadelphia, Pa.

ISSN

0268-1315

eISSN

1473-5857

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

1997, Rapid Science Publishers

Issue

3

Publisher

Wolters Kluwer